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ABSTRACT
Flow Valve Diagnostics for Label-Free, Quantitative
Biomarker Detection: Device Fabrication,
Surface Modification, and Testing
Danielle Mansfield
Department of Chemistry and Biochemistry, BYU
Master of Science
Diseases are often diagnosed by detection of disease-specific biomarkers in fluid
samples. However, many state-of-the-art detection methods require a lab with complex
machinery, trained operators, and/or lengthy analysis time. In contrast, point-of-care
(POC) devices are brought to the patient’s location, they are easy to use, and results are
obtained almost immediately. Many current POC devices are too difficult to be used
without a skilled assistant, and although many are able to detect analytes above a
threshold value, they give little or no quantitative information. This work presents the
development of polymer-based microfluidic devices capable of sensing and quantifying
biomarkers in fluid samples in a straightforward manner using a novel biomarker assay
termed “flow valve diagnostics”. In this assay, an antibody-modified
polydimethylsiloxane (PDMS) microchannel constricts due to the binding force between
antibodies and antigens, stopping fluid flow. The flow distance is measured and
correlated to antigen concentration. This detection method is an improvement over
other methods because it is an innovative, non-instrumented, label-free, easy-to-use
approach. These devices are small, portable, disposable, inexpensive, and thus ideal for
use in POC testing.
I have successfully fabricated flow valve devices with standard micromachining
techniques, including photolithography, replica molding with PDMS, and plasma
oxidation. Following fabrication, I compared two methods for attaching receptor
biomolecules (e.g., antibodies) to the microchannel surfaces: non-specific adsorption
and silanization with 3-glycidoxytrimethoxypropylsilane (GOPS). I used laser-induced
fluorescence to determine that silanization with GOPS was the better method for
biomolecule attachment. Finally, I tested antibody-modified flow valve devices with
target antigens to determine if the antibody/antigen binding force was strong enough
to cause channel pinching and flow stoppage. By modifying the device design and
using higher antigen concentrations, I was able to show that flow valve devices can
detect antigens in a concentration-dependent manner. Future work to improve the
device design and to modify and test these devices with different receptor/target pairs
will bring flow valve diagnostics closer to becoming a valuable asset in biomarker
detection and POC testing.
Keywords: biomarker detection, point-of-care testing, label-free, quantitative, PDMS
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1. INTRODUCTION
1.1 Motivation
In the past 20 years, the high interest in microfluidics is a clear indication that it
is indeed a small world after all. Microfluidics deals with the precise control of fluid
samples at the sub-millimeter scale. Separation scientists developed microfluidics to
improve the analytical performance of methods such as chromatography through
miniaturization. This led to the idea of a “miniaturized total analysis system” (µ-TAS)
or “lab-on-a-chip,”1 a device capable of integrating sample preparation, handling,
analysis, and detection.
Microfluidics has several advantages when compared with traditional analysis
methods. First, the micromachining techniques used to make microfluidic devices come
from the semiconductor industry. Because of this, microfluidic devices share many of
the same desirable qualities as electronic microchips, including small size, high speed,
low cost, scalability, and portability. Second, by nature of their size, microfluidic
devices require only small sample volumes. This is a distinct benefit when dealing with
limited sample volumes or samples containing dangerous chemicals. The small size of
microfluidic devices also leads to lower reagent consumption and thus lower cost.
Finally, a microfluidic device has the potential to reduce human error and
contamination through integration and automation of sample preparation and
handling.
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1.2 History
The first use of micromachining for miniaturization and integration with
electronics was a gas chromatograph with an injector and thermal conductivity detector
integrated on a 5-cm diameter silicon chip.2 Although this device was published in 1979,
silicon-based miniaturization of analytical methods did not receive much attention until
the late 1980s and early 1990s. In 1990, a miniaturized open-tubular liquid
chromatograph with a conductometric detector on a 5 × 5 mm silicon wafer sparked
new interest in creating complete analytical systems on a single, small chip.3 Although
this liquid chromatograph was not functional, the theoretical separation efficiency was
8,000 and 25,000 plates in 1 and 5 minutes, respectively. These efficiencies were
calculated from the physical dimensions of a channel (such as internal and external
column diameter and the thickness between channel walls) and not actual experimental
data, however, this work showed that miniaturization of such a device was both
feasible and could give acceptable separation efficiency in a minimal amount of time.
Many of the first µ-TAS setups utilized capillary electrophoresis (CE) to separate
mixtures.4-8 This advance revolutionized the field of microfluidics and made it a
popular platform for research as it allowed for rapid analyte movement and separation
without valves or pumps. One of the first examples of a µ-TAS capable of rapid analysis
was a planar chip that used CE to separate amino acids in 15 seconds with a separation
efficiency of 75,000 theoretical plates and the same separation in less than 4 seconds
with a separation efficiency of 600 theoretical plates.4
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The materials used to make microfluidic devices have changed as the field has
developed. Early microfluidic devices were fabricated with materials familiar to the
semiconductor industry, namely silicon and glass. Glass was a more popular substrate
for microfluidic devices because of its electrical and optical properties. The chemical
makeup of glass allows for the application of high separation voltages, and because
glass is transparent it can be used with UV-visible optical detection methods. In recent
years polymers have gained prevalence as a material for microfluidic devices, especially
because polymers are inexpensive and because polymer-based microfluidic devices are
relatively easy to produce.9 Polymers commonly used to make microfluidic devices
include polymethylmethacrylate (PMMA) and polydimethylsiloxane (PDMS).
1.3 Biomarker Detection and Point-of-Care Testing
As the field of microfluidics became more popular it started to gain the interest
of not only electrical engineers and analytical chemists, but also biologists and
biochemists. Microfluidics showed great promise in biology and biochemistry because
of its ability to precisely separate and control reagents, allowing for careful monitoring
of complex biological systems. Publications soon began to appear using a microfluidic
platform for biological, clinical, and medical applications, such as genetic analysis10 and
clinical diagnostics.11
In order to simplify clinical diagnostics and make them more accessible,
researchers started to design microfluidic devices capable of sensing biomarkers. A
biomarker is a substance produced by an organism that can indicate a disease state or
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its physiological condition. Thus, measuring the levels of specific biomarkers can help
clinicians diagnose, monitor, and treat illness. Traditional methods for biomarker
analysis include enzyme-linked immunosorbent assays (ELISAs),12 microarrays,13
electrochemical methods,14 and mass spectrometry,15 but not all are particularly suited
for miniaturization and simplification. Most of these methods must be carried out in a
clinical or research laboratory by skilled technicians. These procedures may also be
expensive, call for complex machinery, or require a long wait between the time of the
test and receiving results.
In contrast, point-of-care (POC) testing is a type of clinical diagnostics that brings
biomarker testing to the patient’s location and can provide immediate, straightforward
information about an illness. Additional advantages include low cost, disposability,
potential for multiplexing, and low sample and reagent consumption. These
characteristics make POC testing an attractive option for at-home self-diagnosis,
humanitarian efforts in developing countries, or when rapid and/or frequent testing is
necessary. Because POC testing shares many of the same qualities as microfluidic
testing, microfluidics is an ideal system for POC testing.
1.4 Current Directions in POC Testing
According to the World Health Organization, the ideal microfluidic POC device
would be ASSURED: Affordable, Sensitive, Specific, User-friendly, Rapid and robust,
Equipment-free, and Deliverable to end-users.16 Much of the current research in POC
testing is focused on developing devices with most or all of these attributes. Two areas
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of POC testing that follow the ASSURED model and are especially relevant to this thesis
are lateral flow tests (a.k.a. immunochromatographic tests) and microfluidic paperbased analytical devices (µPADs).
Lateral flow tests are simple immunoassays (see Section 1.8.1) that are wellsuited for POC testing. In a lateral flow test, sample is applied to a solid dipstick and
flows by capillary action along a nitrocellulose strip. As the sample flows, it mixes with
a colored reagent (e.g., gold nanoparticles17, 18) conjugated to antibodies specific to the
target analyte. Further along the strip is a test region containing a different antibody
specific to the same target. If the antigen of interest is present in the sample, it will bind
at the test region, producing a colored line. Presence of a second colored line called the
control line indicates that the test worked properly. The best and most well-known
example of a lateral flow test is the home pregnancy test.17 Lateral flow tests have also
been used to detect infectious agents, metabolic disorders, drugs, and toxic
compounds.19
µPADs are POC devices made of patterned paper20 and were developed to be
inexpensive, diagnostic tests for use in developing countries. µPADs are made by
defining hydrophilic channels and hydrophobic barriers on chromatography paper
with photolithography (see Section 1.5.1). In an assay, sample travels up the channels
and into test zones containing assay reagents, leading to a color change (colorimetric
assay) or an electrochemical response (electrochemical assay) that is associated with the
concentration of the analyte. In colorimetric assays, the µPAD may be photographed or
scanned and sent to an off-site laboratory where trained personnel can analyze the
5

image and recommend further action.21 Thus far, µPADs based on colorimetric assays
have been used for analysis of glucose, proteins, pH, and alkaline phosphatase.21-24
µPADs based on electrochemical detection have been used for analysis of heavy metal
ions, glucose, lactate, and uric acid.25, 26
Lateral flow tests and µPADs are good platforms for POC testing due to their
simplicity, ease-of-use, portability, speed, low cost, and lack of instrumentation.
However, these methods would be more useful if they provided accurate quantitative
information about biomarkers. Although qualitative information about biomarkers may
be sufficient in some cases, quantitative information gives experts a better idea about
the state and severity of a disease, giving patients the best chance to receive the most
beneficial and timely treatment.27 Generally, lateral flow tests give only qualitative
information, indicating whether or not a target is present above a threshold level.
µPADs can give quantitative information, but accurate quantification depends on
consistent image lighting, expert examination, and increased analysis time. So although
lateral flow tests and µPADs are very useful, an assay that follows the ASSURED model
and gives quantitative information about biomarkers would be a great asset to POC
testing.
1.5 Micromachining
Many of the micromachining techniques used to fabricate microfluidic devices
have origins in the semiconductor industry. These techniques allow for excellent control
over micrometer-sized features and lead to reproducible devices. Because a general
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knowledge of these techniques is useful for understanding my work, I will discuss
some of the relevant techniques. For more detailed information on micromachining,
please refer to the book Fundamentals of Microfabrication: The Science of Miniaturization.28
1.5.1 Photolithography
Photolithography is one of the most important micromachining techniques due
to its many applications and utility across several scientific disciplines, including
microfluidics. Photolithography is a process that uses light to transfer a design from a
pattern of transmissive and non-transmissive features, called a photomask, to a lightsensitive chemical known as a photoresist. This is often one of the first steps in
producing a microfluidic device. Different photolithographic methods and different
photoresists may be used depending on the desired feature type, size, and resolution,
the choice of substrate for pattern transfer, or to enable integration with subsequent
separation and detection methods.
The first step in transferring a pattern from a photomask to a photoresist is
heating a substrate to remove water or other solvents from the surface (Figure 1.1a). At
this point, an adhesion promoter or primer may be evaporated or spun onto the
substrate to ensure better interaction between the wafer and the photoresist (Figure
1.1b). A thin, uniform layer of photoresist is deposited on the substrate by spin-coating
at several thousand revolutions per minute (Figure 1.1c). This is followed by heating the
substrate to evaporate excess solvent in the photoresist (Figure 1.1d). In the next step,
the photoresist is exposed to UV light through a photomask (Figure 1.1e). The
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photomask protects some regions of the photoresist from UV exposure while other
regions undergo photochemical reactions. After exposure, the substrate is immersed in
a developing solution. Depending on the type of photoresist, the developer will
dissolve either the areas exposed to UV radiation or the areas protected from UV
radiation. Last, the substrate is heated again to further improve photoresist adhesion
and to make the photoresist more robust (Figure 1.1f).

Figure 1.1 – Patterning with photolithography.
Photolithography is a technique that is used to transfer patterns from a photomask to a
photoresist. The basic steps of pattern transfer are a) solvent evaporation, b) adhesion promoter
deposition, c) photoresist deposition, d) a second solvent evaporation, e) exposure to UV
radiation through a photomask, and f) development followed by heating to generate a
photolithographic pattern.

As mentioned above, the type of photoresist dictates which parts of the
photoresist dissolve in developing solution. The two general categories of photoresist
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are called positive and negative, but as only positive photoresists were used in this
thesis I will only discuss the former (Figure 1.2). When positive photoresists are
exposed to UV light, the main or side polymer chains in the unprotected areas of the
resist break apart, causing the exposed areas to become much more soluble in the
developer. When positive resists are developed, the photoresist pattern left on the wafer
matches the pattern on the photomask.

Figure 1.2 – Behavior of positive photoresists.
After UV exposure through a photomask and development, positive photoresists leave a raised
image identical to the pattern on the photomask.

1.5.2 Soft Lithography: Replica Molding
Soft lithography refers to a collection of non-photolithographic techniques
capable of generating micrometer- and even nanometer-sized features.29 These
techniques are called “soft lithography” because they rely on elastomeric organic
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stamps or molds rather than rigid inorganic materials (i.e., silicon) for pattern transfer
and structure fabrication. One such technique is replica molding (Figure 1.3). Replica
molding is a method for duplicating the structure, features, or morphology of a master
mold. Replication of a master mold is straightforward, consistent, and inexpensive, and
duplicates the copy the master mold with nanometer (<100 nm) resolution.29

Figure 1.3 – Replica molding.
A soft lithographic method for creating duplicates of a master mold. (a) A master mold is
fabricated. (b) Prepolymer is poured over the master mold and cured to harden the polymer. (c)
The duplicate is peeled off the master mold. (d) The duplicate is bonded to a polymer slab to
form embedded microchannels.

Replica molding begins with the creation of a master mold by standard
photolithography (Figure 1.3a). Until it breaks or its features degrade, the master mold
may be used repeatedly to produce new duplicates. Next, pre-polymer is poured on the
master mold and the pre-polymer is cured (Figure 1.3b). Finally, the polymer is peeled
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off the master mold (Figure 1.3c) and the duplicate may be bonded with a polymer slab
to create a microfluidic device with embedded microchannels (Figure 1.3d).
Due to several desirable properties, PDMS (Figure 1.4) is a polymer commonly
used for replica molding. As an elastomer, PDMS can replicate micrometer and submicrometer sized features. For the most part, it is chemically inert,30 and it is optically
transparent down to ~300 nm,29 making PDMS devices compatible with detection
schemes such as laser-induced fluorescence. Last, PDMS is inexpensive and durable.

Figure 1.4 – Structure of polydimethylsiloxane (PDMS).
PDMS is a silicon-based polymer popular for fabrication of microfluidic devices.

1.6 PDMS Surface Modification
Although PDMS offers some advantages over silicon and glass for the fabrication
of microfluidic devices, PDMS often requires modification to fit the specific needs of the
experiment. There are many methods for PDMS surface modification, but I will focus
on the two methods I use when making devices: plasma oxidation and silanization.
1.6.1 Plasma Oxidation
Plasma oxidation or activation is an easy method for changing the surface
chemistry of PDMS. Without modification, PDMS is chemically inert and hydrophobic.
These characteristics make it difficult to use PDMS for CE or with aqueous samples.
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Exposure to O2 plasma oxidizes PDMS and creates silanol groups on its surface,31, 32
making PDMS hydrophilic and capable of forming the electric double layer necessary
for stable electro-osmotic flow.33 However, the hydrophilicity is temporary, and if
oxidized PDMS is left exposed to air the polymer chains will migrate to the surface and
the polymer will revert to its original hydrophobic state.34 This reversion can be slowed
if PDMS is immersed in water immediately after oxidation and if it remains stored
underwater, PDMS can remain hydrophilic for months.34, 35
Plasma activation also provides a simple method for irreversibly bonding PDMS
to glass or to itself. Plasma activation forms siloxane radicals on the surface of PDMS,
and if it is brought into conformal contact with another piece of activated PDMS or
glass, covalent siloxane bonds are formed.33 This an easy method for forming
embedded, hydrophilic microfluidic channels.
1.6.2 Silanization

Figure 1.5 – Silanization of PDMS.
A surface modification method for forming self-assembled monolayers on PDMS. The silane
R-group may be chosen to give PDMS a specific chemical functionality.

Silanization is a method for forming self-assembled monolayers on silicon-based
surfaces such as PDMS (Figure 1.5). To silanize PDMS, the polymer is first plasma
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oxidized to generate silanol groups on the polymer surface. After oxidation, the PDMS
is exposed to the chosen silane, and the silanol groups react with the silane to create
new siloxane bonds and form the self-assembled monolayer. The silane may have a
specific terminal –R group to confer the desired chemical functionality to PDMS.

Figure 1.6 – Antibody attachment with 3-glycidoxypropyltrimethoxysilane (GOPS).
GOPS-silanized PDMS may form a covalent attachment with an antibody when the epoxy end
group reacts with amine groups on the antibody.

The chemical functionality of the silane end group makes it possible to conjugate
biomolecules to PDMS. Of particular interest to this thesis is the ability to functionalize
PDMS with antibodies. One readily available silane that can react with antibodies is 3glycidoxypropyltrimethoxysilane (GOPS) (Figure 1.6). GOPS has an epoxy end group
that can react with the amine side chain of the amino acid lysine to form a covalent
attachment.
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Although GOPS silanization is convenient method for attaching antibodies to
PDMS, this method has its drawbacks. Water is required to facilitate bonding between
GOPS and oxidized PDMS. However, water may also react with the epoxy end group
on GOPS and destroy its ability to bond with amine groups on an antibody, defeating
the purpose of the silanization. To alleviate this problem, I used fresh GOPS to silanize
PDMS and reacted the silanized PDMS with antibody immediately after silanization
(see Section 2.3).
1.7 Detection Schemes
The most important aspect of a diagnostic POC device is its ability to detect and
quantify the biomarkers of interest. This can be particularly difficult when working
with small sample volumes and trying to detect biomarkers only present in limited
amounts. There are currently many methods for detecting biomarkers, but not all of
them are easily integrated with sample preparation and analysis as would be necessary
for a µ-TAS, nor are all of them suitable for POC testing. Therefore, a new detection
scheme that meets the requirements of a POC µ-TAS would be a great addition to the
field.
1.7.1 Electrochemical Detection
Electrochemical detectors operate by monitoring the resistance of a solution or
current from an electrochemical process in a solution and are respectively known as
conductometric or amperometric detectors.36 Conductometric detectors work because
the resistance of a solution of buffer is often different from the resistance of a solution
14

with both buffer and analyte. In an amperometric detector, an applied potential forces
the analyte to undergo a redox reaction, producing a current that is related to the
analyte concentration.
One of the earliest examples of electrochemical detection on a POC device was a
blood oxygen monitor developed by Clark and Lyons in 1962.37 This work used
electrodes to monitor blood oxygen, carbon dioxide, and pH. Clark and Lyons also
suggested the possibility of combining an electrode with an enzyme-containing
membrane to additionally monitor blood glucose concentration, which would work as
follows: (1) The enzyme glucose oxidase catalyzes the oxidation of glucose to gluconic
acid. (2) Electrons from glucose are transferred to an oxidizing agent, which in turn
transfers these electrons to an electrode, producing a current proportional to the
amount of glucose in the blood. This idea led to the development of modern blood
glucose monitoring systems, one of the most successful and widely used POC devices
today.
1.7.2 Laser-Induced Fluorescence
Laser-induced fluorescence (LIF) is one of the most sensitive analytical detection
techniques. In this method, a laser excites fluorescent molecules from an electronic
ground state to a high-energy excited state. After a short time (10-5 to 10-9 s), the
molecules return to the ground state and emit light with a longer wavelength than the
laser.38 The emitted photons are detected by a photomultiplier tube (PMT) or a chargecoupled device (CCD) and converted to an electrical signal.

15

To achieve maximum sensitivity with LIF, several factors must be considered.
First, background emission from sources other than the analyte must be eliminated or
minimized. These sources include scattered laser light, fluorescence from the buffer and
the device, Rayleigh scattering, and Raman scattering. Minimization of background
emission may be achieved with optical filters and irises.
Like any detection method, LIF has both advantages and disadvantages. LIF is
highly sensitive and can detect single particles.39 It is also a useful method for visually
monitoring an analyte’s location in and progress through a device. A disadvantage of
LIF is the need for large, delicate, and expensive hardware. In addition, analytes may
need to be labeled before they can be detected, and signal may decrease over time due
to photobleaching.
1.8 Biomarker Assays
A biomarker assay is a complete analytical procedure for assessing the presence
and/or the amount of biomarker present in a sample. Traditional biomarker assays
such as immunoassays are specific and sensitive, but do not translate easily into a POC
device. In this section I will introduce a new biomarker assay that I have helped
develop called “flow valve diagnostics.” This assay is both quantitative and fit for POC
applications.
1.8.1 Immunoassays
An immunoassay is a biochemical test that detects the presence of or measures
the concentration of specific analytes in a sample using antibody/antigen interactions.
16

In these tests, binding of an antigen and an antibody leads to a detectable response,
often a color change, which indicates the presence and amount of analyte. Depending
on the type of immunoassay, either the antigen or the antibody may be the analyte of
interest. The sensitivity of an immunoassay depends on specific binding between the
antibody and the antigen without interference from other compounds in the sample.
Some examples of immunoassays are enzyme-linked immunosorbent assays (ELISAs)
and lateral flow tests (see Section 1.4).
The sandwich ELISA method detects antigen in a sample by using two
monoclonal antibodies. A primary antibody is adsorbed to the bottom of a well of a
microtiter plate. Sample is added to the well. If the sample contains the antigen specific
to the primary antibody, the antigen will bind. A second, enzyme-linked antibody is
added to the well. This secondary antibody binds to a different epitope of the antigen of
interest, and thus “sandwiches” the antigen between the two antibodies. After unbound
secondary antibody is removed by washing, the enzyme activator is added to the well,
which causes the solution to change color. The rate of color formation is proportional to
the amount of antigen in the sample. These tests can detect less than a nanogram of
analyte.40
The ELISA is one of the most sensitive and specific biomarker assays, but it is not
very compatible with POC testing. First, ELISAs are comprised of several steps, making
them time-consuming and laborious. Second, they are only cost-effective if performed
on many samples at once (e.g., 96 samples in a microtiter plate). Last, trained personnel
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are required to perform the assay. Until these disadvantages are overcome, the ELISA
will remain a lab-bound technique.
1.8.2 Flow Valve Diagnostics
The Woolley laboratory has developed a novel biomarker assay termed “flow
valve diagnostics” that is well suited to POC testing (Figure 1.7). In this new method, a
flexible PDMS microchannel coated with receptor molecules (Figure 1.7a) acts as a selfconstricting valve due to binding of receptor and target molecules (e.g., antibodies and
antigens). When a sample containing target molecules flows through a receptor-coated
PDMS microchannel, the binding force between target and receptor causes the
microchannel to constrict and prevent fluid from flowing further in the channel (Figure
1.7b). This flow stoppage can be detected by the naked eye because the refractive

Figure 1.7 – Flow valve diagnostics.
A receptor-functionalized polymer microchip capable of detecting the presence of biomarker in
a label-free manner. Features are not to scale and have been exaggerated to show detail.
a) Sample containing no target flows freely through the channel. b) Sample containing
biomarker results in target/receptor binding, causing the flexible polymer to constrict and stop
fluid flow.
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indices of air in an empty microchannel and fluid in a filled microchannel are
sufficiently different that it is easy to distinguish the empty portion of a microchannel
from the filled portion of a microchannel.
One of the great advantages of flow valve diagnostics is that it is a quantitative
POC technique. Preliminary work done by Debolina Chatterjee using the model
target/receptor system of streptavidin-biotinylated-bovine serum albumin (BSA)
indicates that there is a linear relationship between flow distance (i.e., how far the
sample flowed in the microchannel before valve constriction prevented further flow)
and log10[streptavidin].41 Therefore, the flow distance can be measured and used to
ascertain the target concentration in a sample. As there are few simple, inexpensive, and
quantitative POC methods, flow valve diagnostics has the potential to meet a specific
need in the realm of POC testing.
To make flow valve devices generally applicable, I would like to use diseasespecific antigens and their corresponding antibodies. Consequently, the focus of this
thesis is modifying PDMS microchannels with antibodies and performing flow valve
assays with antigen solutions.
1.9 Thesis Overview
In this thesis I will discuss developing flow valve devices by modifying the
surface chemistry of PDMS to allow for the attachment of biomolecules such as
antibodies. Chapter 2 introduces the device fabrication and surface modification
processes. Chapter 3 presents testing of antibody-modified flow valve devices. Last,
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Chapter 4 discusses conclusions that may be drawn from my work and future
directions for this research.
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2. FABRICATION AND SURFACE MODIFICATION OF FLOW VALVE DEVICES
2.1 Introduction
In this chapter I present fabrication methods for flow valve devices. I used wellestablished micromachining techniques to create many PDMS flow valve devices.
Briefly, the fabrication process begins with making a master mold (Section 2.2.1),
followed by replica molding of PDMS on the master mold to create the layer of the flow
valve device containing the microfluidic channels (Section 2.2.2). The channel layer of
the device is bonded to a PDMS slab, after which the embedded microchannels are
functionalized with receptor molecules (e.g., antibodies) to prepare the devices for use
in flow valve assays (Section 2.2.3).
2.2 Experimental
2.2.1 Mold Fabrication
The mold fabrication process is summarized in Figure 2.1. Glass was chosen as
the mold substrate because it breaks less easily than silicon. Also, initial device
fabrication attempts indicated that PDMS was less likely to permanently adhere to glass
than to silicon. The wafer was rinsed in acetone and isopropyl alcohol. After rinsing,
any residual organic material was removed in a Planar Etch II plasma etcher (Technics
West, San Jose, CA) with an oxygen plasma for 3 min at 250 W. Following the etching,
water was removed from the wafer by drying in an Ultra-Clean 100 oven (Lab-Line
Instruments, Melrose Park, IL) for 15 min at 150 ºC. Hexamethyldisilizane (HMDS, SPI

27

Supplies, West Chester, PA) was evaporated onto the wafer to promote photoresist
adhesion (Figure 2.1a). Next, the wafer was spin-coated with a positive photoresist,
heated to remove any residual solvent, and allowed to rehydrate in air at room
temperature for 45 min.

Figure 2.1 – Mold fabrication for flow valve devices.
A master mold for replica molding of flow valve devices is created using standard
photolithographic techniques. a) After cleaning, dehydrating and priming the glass wafer, it is
ready for photoresist depostion. b) Following spin coating of the photoresist and rehydration,
the photoresist is exposed to UV light through a photomask. c) The wafer is developed to
dissolve exposed photoresist. d) The wafer is reflowed to achieve a semicircular feature
geometry.

I chose to use AZ series positive photoresists for pattern definition on my molds,
specifically AZ 3330F, AZ P4620, and AZ 50XT (AZ Electronic Materials, Branchburg,
NJ). These photoresists allowed me to achieve various channel heights when optimizing
the device design while also offering reflow capabilities (see Table 2.1). Initial
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fabrication was done with AZ 3330F, giving channels from 5-7 µm tall. When I desired
taller channels, I moved to the thicker photoresist AZ P4620, and I was able to make
channels 7-13 µm tall. For channels taller than 13 µm, I used AZ 50XT.
Table 2.1 – Select Photolithographic Recipes for Specific Microfluidic Channel Heights

After photoresist rehydration, the wafer was exposed to UV light from a 250 W
mercury lamp in a MA150 CC Karl Suss Aligner (Karl Suss America, Waterbury Center,
VT) through a photomask (Figure 2.1b), followed by a post-exposure bake, if necessary
for the photoresist (see Table 2.1). The wafer was then developed (Figure 2.1c) in the
appropriate developer (AZ Electronic Materials; see Table 2.1) and reflowed to achieve
a semicircular feature geometry (Figure 2.1d).
Reflowing, or heating the photoresist to a temperature above its
melting point after exposure and development, changes microfluidic channel geometry
from rectangular to semicircular.1 A semicircular channel geometry is desirable for flow
valve channel constriction because it is easier for a curved channel to pinch shut from
the sides toward the center than a rectangular channel.2 Unger et al. demonstrated the
validity of this principle for valves closed by actuated pressure, with semicircular
channels closing easier than rectangular channels.3
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I used two photomask designs to make device molds (Figure 2.2). The first
design contained five flow valve devices with 35 mm-long straight channels (Figure
2.2a), while the second design contained 4 three-lane devices, 2 five-lane devices, and 3
nine-lane devices, all with serpentine channels of varying length (Figure 2.2b). Of the
serpentine devices, I mainly used the five-lane devices, which had five 36 mm-long
channels connected by rounded corners. The straight channel devices were simple and
easy to use, but did not allow for a low limit of detection. On the other hand, the
serpentine devices were more difficult to work with, but were able to achieve a lower
limit of detection due to the longer channels.

a)

b)

Figure 2.2 – Photomask designs for device fabrication.
a) The straight channel design produces 5 devices with 35-mm long channels. b) The serpentine
channel design produces 4 three-lane devices, 2 five-lane devices, and 3 nine-lane devices with
straight channels of varying length connected by rounded corners.

The height and width of the channels on the completed master molds was
determined with an Alpha-Step 200 profilometer (Tencor Instruments, Milipitas, CA).
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2.2.2 Flow Valve Device Fabrication
Flow valve devices were prepared by casting PDMS against a master mold
(Figure 2.3). PDMS (Dow Corning, Centennial, CO) was prepared by mixing the base
and curing agents in a 10:1 ratio and was degassed for 30-60 min. PDMS was then
poured on the master mold to a thickness of 0.5 mm and cured at 80 ºC for 45 min
(Figure 2.3a). A separate layer of the device was prepared by spinning a thin slab of
PDMS onto glass microscope slides and also curing at 80 ºC for 45 min (Figure 2.3b).

Figure 2.3 – Flow valve device fabrication.
Replica molding enables the fabrication of many flow valve devices with a single master mold.
a) Pre-polymer is poured over the master mold and baked. b) Cured PDMS is peeled off the
master mold, and the second layer of the device is prepared by spinning and curing PDMS on a
glass slide. c) The two PDMS layers are joined by plasma bonding to complete the device.

To complete the devices, the patterned PDMS was peeled off the master mold
(Figure 2.3b) and bonded to the PDMS-covered slides (Figure 2.3c). After both layers
were exposed to an oxygen plasma they were bonded by being brought into conformal
contact with one another,4 forming a flow valve device with embedded channels. The
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devices were either stored in water or used immediately to prevent loss of
hydrophilicity.5, 6
2.2.3 PDMS Surface Modification for Antibody Attachment
The first method I tried to attach antibodies to PDMS was non-specific
adsorption. Biomolecules tend to adsorb non-specifically to PDMS,7 and this
characteristic is usually detrimental to microfluidic systems. However, as non-specific
adsorption was an acceptable method for functionalizing PDMS with biotinylated-BSA
during proof-of-concept testing (see Section 3.2), I wanted to see if I could take
advantage of this trait as an easy method to attach antibodies to the channel walls.
Immediately following plasma oxidation and bonding of the device, 1.5 µL of
fluorescein isothiocyanate (FITC)-conjugated rabbit polyclonal anti-streptavidin
(Abcam, Cambridge, MA, 10 mg/mL in 0.02 M phosphate, 0.15 M NaCl, 0.01% sodium
azide, pH 7.2) was introduced into a designated liquid reservoir and allowed to adsorb
for 60 min. To prevent the antibody from drying out, the devices were kept in a humid
environment by keeping them in a Petri dish with a moist paper towel. After antibody
adsorption, excess solution was removed from the channels by applying vacuum.
Unadsorbed antibody was removed by rinsing the channels with 1 µL of distilled water
or phosphate buffer.
I also explored silanization as an alternate method for attaching antibodies to
PDMS. A silane solution was prepared by mixing 0.4-1 mL GOPS (Sigma-Aldrich, St.
Louis, MO) in 20-40 mL toluene (Sigma-Aldrich) or methanol (Sigma-Aldrich).

32

Immediately following plasma oxidation, the flow valve devices were submerged in the
silane solution for 60 min. After silanization, the devices were removed from the silane
solution and rinsed with solvent to remove unreacted GOPS and the channels were
drained of any residual silane solution. A 1.5 µL sample of FITC-conjugated antistreptavidin (1 mg/mL in 0.02 M phosphate, 0.15 M NaCl, 0.01% sodium azide, pH 7.2)
was pipetted into the channel reservoir, filling the channel, and reacted with the GOPS
for 60 min. The devices were once again covered with a damp paper towel to prevent
the antibody solution from drying out. Finally, excess solution was removed from the
channels and the channels were rinsed with water or phosphate buffer.
2.2.4 Characterization of Modified Devices with Laser-Induced Fluorescence
I used LIF to characterize the antibody-modified devices to determine whether or
not the methods were efficiently modifying the channel surfaces. This also allowed me
to decide which modfication method, non-specific adsorption or silanization, was the
best method for attaching antibodies to PDMS.
The LIF system consisted of a 625 mW LED (MBLED, Thorlabs, Newton, NJ)
passed through a filter cube (FITC-LP01-Clinical-OMF, Semrock, Rochester, NY) and an
upright microscope (Axio Scope, A1, Zeiss, Thornwood, NY), which was connected to a
CCD camera (CoolSNAP HQ2, Photometrics, Tucson, AZ). Exposure time was 500 ms.
Devices were imaged after GOPS silanization but before antibody adsorption and also
following antibody adsorption and rinsing with distilled water.
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During surface modification with FITC-anti-streptavidin, care had to be taken to
avoid photobleaching of the FITC. The fluorescently conjugated antibody was stored in
an opaque container and was only pipetted in a dark room. Devices reacting with FITCanti-streptavidin were covered and kept in a dark room until imaging was complete.
The laser was shuttered in between images to prevent photobleaching of the antibody
by the laser.
Images were processed and analyzed with ImageJ software.8 A square box was
drawn on each image and probed for average fluorescence intensity and standard
deviation.
2.3 Results and Discussion
The fabrication procedure described in Section 2.2.2 produced PDMS devices
with semicircular channels with width and height matching that of the master mold
used to make the replica. Figure 2.4 shows photographs of a completed straight channel
device (Figure 2.4a) and a serpentine channel device (Figure 2.4b).

Figure 2.4 – Completed a) straight channel and b) serpentine channel devices.
a) The straight channel devices had channels 35 mm-long and were made using the long arm of
an existing offset-T design. b) The serpentine channel devices consisted of five 36 mm-long
channels connected by rounded corners.
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To ensure that plasma bonding produced enclosed channels and that dust or
other debris was not blocking the channels, a 1 µL sample of distilled water was added
to one channel reservoir and allowed to flow through the channel. If the water
completely filled the channel without difficulty the device was considered testable,
otherwise the device was considered defective and was thrown away.
Fluorescence images were obtained for antibody in complete devices with
enclosed channels. Figure 2.5 shows images of a plasma oxidized but unsilanized device
before, during, and after exposure to FITC-anti-streptavidin.

Figure 2.5 – LIF images of a plasma oxidized, unsilanized flow valve device.
The red lines indicate approximate channel boundaries. Channel width is 50-60 µm. a) An airfilled microfluidic channel before introduction of the antibody. b) The microfluidic channel
filled with FITC-anti-streptavidin. c) The microfluidic channel after flushing out unadsorbed
antibody with distilled water.

Fluorescence images of plasma oxidized but unsilanized devices indicated that
antibody could adsorb to PDMS by non-specific adsorption alone, but most often the
primary location of antibody adsorption was at the channel edges and not the entire
surface of the channel. This increased fluorescence at channel edges was also apparent
in GOPS-modified PDMS devices (Figure 2.6).
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Figure 2.6 – Increased fluorescence at channel edges in two silanized devices.
Fluorescence images of two GOPS-silanized devices after removing unreacted antibody. The
red lines indicate approximate channel boundaries. Channel width is 50-60 µm. The
fluorescence at the channel edges is more intense than fluorescence in other parts of the
channel.

There are two possible explanations for the accumulation of fluorescence at the

channel edges. First, due to the channel geometry it was favorable for liquids to pool
along the edges of the channel where high surface tension would allow them to escape
the vacuum that drained liquid from the channel. Second, the top down perspective of
the microscope in addition to the curvature of the channel walls (Figure 2.7) produced
an edge effect that could make it appear as if there was more fluorescence at the edges
of the channel.

Figure 2.7 – Microscope edge effect.
The top-down microscope perspective combined with narrow depth of field and curved
channel edges could lead to deceptively bright fluorescence signal at the channel edges.
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Difficulty draining the enclosed channels of unadsorbed antibody led to testing
for antibody adsorption on GOPS-modified PDMS slabs. It was much easier to rinse
antibody from a flat PDMS slab than from an enclosed channel. Figure 2.8 shows LIF
images of a GOPS-modfied PDMS slab before, during, and after exposure to FITCstreptavidin. These images indicate that attaching antibodies to PDMS through
silanization was a viable option and that it appeared to attach more antibodies than
non-specific adsorption.

Figure 2.8 – LIF images of a GOPS-modified PDMS slab.
a) A GOPS-silanized PDMS slab before introduction of the antibody. b) The slab with FITC-antistreptavidin on the surface. c) The slab after rinsing off unadsorbed antibody with distilled
water.

Although imaging PDMS slabs allowed for better removal and rinsing of
unadsorbed antibody, lack of an adequate focal point such as a channel edge led to
many unfocused images and thus inaccurate representations of fluorescence. Thus, I
imaged unenclosed PDMS channels exposed to the air. This gave me a channel edge to
focus on while still allowing for easy rinsing and removal of unadsorbed antibody. The
microscope edge effect is still apparent in images obtained by this method, but it
allowed for a better comparison of antibody attachment on unsilanized and silanized
PDMS.
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Fluorescence images (Figure 2.9) show two unsilanized (but plasma oxidized)
PDMS devices (two leftmost columns) and two GOPS-silanized PDMS devices (two
rightmost channels) before (top row), during (middle row), and after (bottom row)
exposure to FITC-anti-streptavidin. After rinsing, the GOPS-silanized PDMS channels
had an average fluorescence intensity of 2300 ± 1200 and 1700 ± 1000 while the
unsilanized PDMS channels had an average fluorescence intensity of 1200 ± 700 and 500
± 200. The large standard deviations indicate that there was significant variability in
fluorescent intensity from point to point in the channels. Despite the large standard
deviations, these results point to GOPS-silanization offering a higher surface coverage
of attached antibodies on PDMS.

Figure 2.9 – Comparison of antibody adsorption in unsilanized and silanized unenclosed
PDMS devices.
LIF images of FITC-anti-streptavidin in two unsilanized (only plasma oxidized) PDMS devices
and two GOPS-silanized PDMS devices. The red lines represent approximate channel
boundaries. Channel width is 60-70 µm. The top, middle, and bottom rows respectively show
the PDMS before, during, and after antibody exposure.
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Silanization is also advantageous because it ensures a covalent attachment
between the antibodies and the PDMS and because it should make more antibodies
attach in the proper orientation for antigen binding. However, disadvantages to the
silanization method include the time required, GOPS’ reactivity with water, and PDMS
solvent compatibility. First, the current silanization attachment method is 2-3 times
longer than attachment by non-specific adsorption. Further testing could be done to see
if the silanization and/or the antibody attachment steps could be shortened with no loss
in the amount of antibody attachment. Second, GOPS’ reactive terminal epoxy ring is
sensitive to reaction with water, and if GOPS and water react, GOPS can no longer react
with antibodies. Therefore, care must be taken to prevent exposing GOPS to water
before it can react with the antibodies. This leads to the final issue, PDMS solvent
compatibility. Because GOPS is water reactive, the silanization solvent is normally
hydrophobic, with toluene being the normal solvent of choice. However, PDMS is
incompatible with many organic solvents as it absorbs some solvents and swells.9 This
swelling is particularly detrimental as it can cause PDMS plasma bonds to break,
compromising the integrity of a device.
I used several methods to overcome these issues with the silanization method for
antibody attachment. First, I purchased a new, septum-capped bottle of GOPS that had
not been exposed to water, as even minimal water exposure will cause a bottle of GOPS
to degrade in 6-8 months. Second, all GOPS solutions were used immediately and flow
valve devices were tested immediately after all silanization steps to prevent the GOPS
from reacting with water in the air or solvent. I did, however, have to compromise on
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the silanization solvent. Toluene made the PDMS swell, breaking the plasma bond
between the two device layers, so I had to find a new solvent. I tested three common
solvents: acetone, ethanol, and methanol. According to Lee et al.,9 these three solvents
would not significantly swell PDMS, with methanol swelling PDMS the least, so I chose
to use methanol as the silanization solvent. Although methanol is hydrophilic, I used
the purest methanol available (≥99.9%) to reduce the likelihood of water contamination.
2.4 Conclusions
This chapter presents the fabrication of flow valve devices using standard
micromachining techniques, including photolithography, replica molding, and plasma
oxidation. The devices may be modified by plasma oxidation and silanization to
facilitate biomolecule attachment. LIF analysis of unsilanized and GOPS-silanized
devices indicated that silanization is the better method for attaching antibodies to
PDMS microchannels.
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3. TESTING OF FLOW VALVE DEVICES
3.1 Introduction
With the flow valve device fabrication and surface modification processes
established, the next step in device development was to prove that these devices could
be used to detect and quantify biomarkers. To do this, I performed two types of tests.
First, I studied proof-of-concept tests with biotin acting as the receptor bound to the
microchannel walls and streptavidin acting as the target (biomarker) to be detected.
Second, once the effectiveness of the proof-of-concept tests was verified by other group
members, I began performing tests with anti-streptavidin (receptor) and streptavidin
(target) as a more realistic approximation of the target/receptor interactions that would
be useful for analyzing biological fluid samples.
3.2 Proof-of-Concept Testing
Initial testing of flow valve devices was with a simple, effective, and well-studied
target/receptor pair: streptavidin and biotin. The streptavidin-biotin bond has a
dissociation constant (Kd) of ~10-14, making it one of the strongest known non-covalent
interactions.1 Streptavidin is also a tetramer with four identical subunits and thus can
bind up to four biotins at one time. Due to these qualities, the streptavidin-biotin system
was ideal for proof-of-concept testing.
The proof-of-concept testing procedure has been described elsewhere2 but is
summarized here for reference and convenience. Immediately after plasma bonding
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and oxidation, the microchannels of the flow valve devices were filled with
biotinylated-bovine serum album (biotinylated-BSA, Thermo Scientific, Rockford, IL, 2
mg/mL in 0.14 mM citrate buffer, pH 6.8) by capillary action. The biotinylated-BSA was
allowed to adsorb to the channel walls for 15 min. After that time period, unadsorbed
biotinylated-BSA was flushed from the channel using phosphate buffered saline (PBS,
10 mM, pH 7.2). Last, PBS was removed from the channel and 1 µL of streptavidin
solution (New England Biolabs, Ipswich, MA) of known concentration in PBS was
pipetted into the reservoir. Flow distance was recorded with a ruler and images were
obtained with a digital camera.
Results from the proof-of-concept testing indicated that log10[streptavidin] and
flow distance share a linear relationship.2 Therefore, for a given device design, one is
able to create a standard curve and subsequently determine the concentration of
unknown samples by measuring flow distance.
3.3 Antibody/Antigen Testing
After the success of proof-of-concept testing I wanted to demonstrate the wide
applicability of flow valve devices by testing them with antibody/antigen pairs.
Because the best way to detect a biomarker (e.g., antigen) is by using its complementary
antibody, study of an antigen/antibody interaction gives more valuable information
about detecting biomarkers in a biological system using the flow valve method than the
streptavidin-biotin interaction.
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For antibody/antigen testing, antibodies were attached to the channel walls by
the method given in Section 2.2.3. I chose to use anti-streptavidin as the antibody so that
I could continue to use streptavidin as the antigen, as this would provide a good
comparison to proof-of-concept tests. Following rinsing and drying of the channel, a 1.5
µL sample of streptavidin of a given concentration was pipetted into the channel
reservoir and began to move through the channel by capillary action. During initial
testing I was only concerned with whether or not the antibody/antigen interaction was
strong enough to cause the fluid to stop in the channel. I expected that the fluid would
travel further in these channels than in any of the proof-of-concept tests because the
anti-streptavidin/streptavidin interaction is weaker than the biotin/streptavidin
interaction, so it would likely take more extensive binding to stop flow.
Initial tests gave varying results as to whether or not the fluid in the channel had
stopped moving as a result of the flow valve effect. Some trials seemed to indicate that
flow was stopping, while others indicated that flow was not stopping but instead the
fluid flow rate significantly slowed. I thought this might be due to the relative weakness
of the antibody/antigen interaction. However, as the streptavidin samples did seem to
flow more slowly than the blank samples, I thought that the antistreptavidin/streptavidin interaction might be causing the channel to constrict to the
extent that liquid flow would slow but not enough that it would stop completely.
The hypothesis of limited channel constriction led to timed flow testing. Instead
of waiting for the liquid to stop flowing and recording only the final flow distance, I
placed rulers parallel to the channels and recorded the flow distance at 15 sec intervals
45

until either the flow had stopped, the fluid had flowed to the end of the channel, or a
specified amount of time (~15 min) had elapsed. This allowed me to look for trends in
fluid flow to see if there was a time or point where the flow consistently slowed.
Initial timed flow trials were performed in 5-lane serpentine devices with
channels 12.6-13.8 µm tall and 78-86 µm wide. To determine if these antibody-modified
devices exhibited concentration dependent-flow distance, I tested two streptavidin
concentrations: 1.0 mg/mL and 0.33 mg/mL. The average flow distance of several
timed trials (eight with 1 mg/mL and four with 0.33 mg/mL) is shown with error bars
representing one standard deviation in Figure 3.1.

Figure 3.1 – Average flow distances in anti-streptavidin modified flow valve devices for two
streptavidin concentrations in 12.6-13.8 µm tall channels.
Timed flow tests were used to look for trends in flow rate slowing that could have been caused
by limited channel constriction. Although the trials indicate concentration-dependent flow
distance, overlapping of error bars (one standard deviation) likely meant that these streptavidin
concentrations were near the limit of detection for these devices.
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Analysis of the results from these initial timed flow trials appeared to indicate
that there was some concentration dependence; that is, more dilute streptavidin
samples (0.33 mg/mL) generally flowed a greater distance than more concentrated
streptavidin samples (1.0 mg/mL) at a given time. However, repeated experiments
sometimes gave varied flow distance profiles for the same concentration, leading to
overlapping standard deviations for different concentrations.
Overlapping of the error bars for the 0.33 mg/mL samples and the 1 mg/mL
samples indicated that these concentrations could not be differentiated easily in these
antibody-modified flow valve devices. Therefore, I decided to try modifying the device
design by reducing the height of the microfluidic channels to alter the concentration
dependence of flow. A shorter channel should need less flow distance before the
channel constricts enough to slow or stop fluid flow. Thus, the new mold had devices
with channels 9.5-10.4 µm tall and 62-70 µm wide. I made anti-streptavidin modified
devices with this mold and performed timed flow tests with 0 mg/mL streptavidin
(blank) and 1 mg/mL streptavidin. The results are shown in Figure 3.2.
This second set of timed flow trials in shorter channels does verify that shorter
channels have a reduced flow distance for the same concentration than taller channels,
as the 1 mg/mL streptavidin samples in these devices began slowing at a flow distance
of ~90 mm, as opposed to the 1 mg/mL samples in the 12.6-13.8 µm tall channels, which
began slowing at a flow distance of ~120 mm. However, the overlapping error bars of
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the blank and 1 mg/mL samples in these channels indicated that this concentration was
near the limit of detection for the modified device design.

Figure 3.2 – Average flow distances in anti-streptavidin modified flow valve devices for
blank and 1 mg/mL streptavidin in 9.5-10.4 µm tall channels.
The overall flow distance for 1 mg/mL samples was less than the flow distance for 1 mg/mL
samples in taller channels. Overlapping of the error bars (one standard deviation) for 0 mg/mL
and 1 mg/mL samples indicates that 1 mg/mL streptavidin is near the limit of detection for this
device design.

To ensure that the streptavidin samples were above the limit of detection for
these flow valve devices I tested a more concentrated sample. I obtained 1.0 mg of
lyophilized streptavidin and reconstituted it to 10 mg/mL with distilled water (Thermo
Scientific, Rockford, IL, 10 mg/mL in 20 mM potassium phosphate, pH 6.5). This
concentrated streptavidin was tested in channels 12.6-13.8 µm tall and 78-86 µm wide
(similar to the experiments in Figure 3.1).
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The results for the 10 mg/mL streptavidin trials are given in Figure 3.3. The data
clearly show that the 10 mg/mL streptavidin samples traveled less distance (~80 mm)
than the 1.0 mg/mL streptavidin samples before fluid flow slowed and stopped. Also,
the error bars for the 1.0 mg/mL streptavidin samples stopped overlapping with the
error bars for the 10 mg/mL streptavidin samples at approximately the distance where
the 10 mg/mL samples began to slow (~80 mm). In all, these results demonstrate a
concentration-dependent flow valve effect and suggest that with further development
an antibody/antigen system is a viable option for biomarker detection in flow valve
devices.

Figure 3.3 – Average flow distances in anti-streptavidin modified flow valve devices for 1
and 10 mg/mL streptavidin samples.
Different flow distances and non-overlapping error bars (one standard deviation) for 1 mg/mL
and 10 mg/mL streptavidin samples signify the feasibility of using an antibody/antigen
interaction for detection of biomarkers in flow valve devices.
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3.4 Conclusions
These experiments suggest that quantitation of antigens by use of flow valve
devices is possible through an antibody/antigen interaction which leads to channel
constriction and the slowing or stoppage of fluid flow. Although my results were with
an antigen concentration above the typical biomarker concentrations in fluid samples,
the flow valve devices could be modified to improve limits of detection. More research
must be done with new device designs and different antibody/antigen pairs to further
demonstrate the viability of this concept.
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4. CONCLUSIONS AND FUTURE WORK
4.1 Conclusions
I have described the fabrication process for a new kind of POC test called flow
valve diagnostics (see Chapter 2). These devices are easy to make using established
micromachining techniques, allowing for parallel processing of several devices at one
time. The microchips are small and made of inexpensive materials. The PDMS
microchannel may be modified using silane-based surface chemistry to attach
biomolecules, such as antibodies, to the channel surface (see Chapter 2). I evaluated
attachment of antibodies through non-specific adsorption on oxidized PDMS and to
PDMS coated with a reactive silane (GOPS). LIF experiments indicated that GOPSsilanization was a more effective method for attaching antibodies to PDMS.
Flow valve devices can detect and quantify biomarkers due to the interaction
between the receptor biomolecules attached to the channel surface and target
biomarkers in the sample solution (see Chapter 3). The receptor/target interaction
causes the flexible PDMS microchannel to constrict like a valve, slowing and/or
stopping fluid flow in the channel. The distance the sample flowed may then be
correlated to biomarker concentration in the sample. I have demonstrated the use of an
antibody/antigen system for concentration-dependent detection of antigen samples.
Devices modified with anti-streptavidin were able to detect 10 mg/mL streptavidin and
were able to distinguish these samples from 1 mg/mL streptavidin.
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4.2 Future Work
4.2.1 Improve Limits of Detection
Although experiments were able to demonstrate proof-of-concept with flow
valve systems, my experiments using anti-streptavidin and streptavidin were not very
successful below a target concentration of 1 mg/mL. In fact, the best results were
achieved with a 10 mg/mL sample solution, a concentration far higher than the
biological levels of most diagnostic biomarkers. For flow valve devices to be useful for
testing biological samples, the limit of detection must be significantly improved.
There are several device parameters that can be modified to improve the limit of
detection. First, the channel height dictates how quickly channel constriction occurs.
Shorter channels pinch more quickly than taller channels; however, shorter channels
may also lead to clogging and thus incorrect results. Therefore, an optimal channel
height must be determined that allows for efficient channel constriction and a low limit
of detection while avoiding clogging.
Second, the cross-sectional shape of the channel affects channel closure. While
the Woolley group has already determined that a rectangular channel will not close due
to the flow valve effect, a trapezoidal channel shape may work even better than a
semicircular channel shape. It may also be easier to control the angle of trapezoidal
channel walls than it is to control the angle of semicircular channel walls, which is
limited by the reflow step.
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Third, the thickness of the top PDMS layer containing the microfluidic channel
also affects channel constriction. The thinner the top PDMS layer, the easier it is for the
PDMS to flex and constrict. Recent work1 shows that a PDMS layer 0.45-0.5 mm thick is
ideal for testing with biotin/streptavidin. While it is possible to fabricate a PDMS layer
<0.45 mm thick, PDMS becomes difficult to work with and susceptible to tearing at
these thicknesses. I have done some experiments with a commercial 0.250 mm-thin
silicone film (Bisco Silicones HT-6240, Rogers Corp., Rogers, CT) and found this film to
be easier to work with than lab-made thin PDMS. However, I was not able to achieve
consistent bonding for proof-of-concept testing in those initial tests. Therefore, it should
be useful to improve device fabrication with thin silicone films, perhaps by treating the
film prior to plasma bonding to improve adhesion or through alternative bonding
methods, such as thermal bonding. Successful integration of a thin silicone film could
help improve the limit of detection.
Finally, the viscosity of the sample solution plays a role in how fast the channel
constricts. Viscous samples flow more slowly under capillary action, providing more
time for receptors and targets to cross-link and narrow the channel.1 Sample viscosity
can be increased by adding glycerol before testing, but this adds an additional handling
step and dilutes the sample.
One unexplored parameter that may be used to improve the limit of detection is
the amount of receptor attached to the channel walls. If the modification method is not
attaching a sufficient number of biomolecules to the channel, it could take a long time
for channel shrinkage to occur (or it may never occur) despite a sample with high
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biomarker concentration. GOPS may not be the best silane to use for antibody
attachment due to its susceptibility to hydrolysis. Another silane that could be used to
attach biomolecules to PDMS is 3-aminopropyldiethoxysilane (APDIES), which confers
amine functionality (Figure 4.1). The amine functional group can further be activated
with glutaraldehyde and can then readily react with amine groups on biomolecules to
form a covalent attachment. APDIES silanization does not require a solvent; however,
the silanization procedure takes more time and requires use of the toxic chemical
glutaraldehyde. It would be valuable to determine which silanization method attaches
more antibodies to the channel walls. This could be studied by silanizing PDMS and
attaching fluorescent antibodies with each method, then obtaining LIF images and
comparing the fluorescence intensity of GOPS-silanized PDMS to that of APDIESsilanized PDMS or other attachment methods.

Figure 4.1 – APDIES silanization.
APDIES is an alternate silane to GOPS that can be used to attach biomolecules to PDMS.
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4.2.2 PDMS Modification with 2 Monoclonal Antibodies
Receptor molecules attached to the PDMS channels must be able to bind to
multiple locations on the target biomarker in order for channel constriction to occur.
Thus far, I have worked with polyclonal antibodies, which are capable of binding
multiple epitopes of the same antigen. Another method that could achieve the same
outcome is to use two monoclonal antibodies. Monoclonal antibodies can bind only a
single epitope on an antigen, but using two monoclonal antibodies that bind to different
epitopes would enable channel narrowing as antigen flowed through the channel.
Modification with two monoclonal antibodies could be done by mixing equal amounts
of each antibody before adding them to the silanized channel.
Monoclonal antibodies are more specific than polyclonal antibodies,2 which
could be an advantage if a sample contained non-target antigens with epitopes similar
to those on the target antigen. Monoclonal antibodies are also more homogeneous than
polyclonal antibodies,2 so monoclonal antibodies could potentially give more
reproducible results. However, monoclonal antibodies are much harder to produce and
thus more expensive than polyclonal antibodies, making flow valve devices modified
with two monoclonal antibodies more costly.
4.2.3 PDMS Modification and Testing with DNA/RNA Oligomers
Biomarkers are not limited to antigens. Certain DNA or RNA oligomers can also
be used as diagnotic biomarkers. Therefore, it would be useful to modify flow valve
devices with DNA/RNA receptors and test these devices with the complementary
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oligomer sequence. The sequences of the receptors and targets must be carefully
designed so that it is most favorable for the target to bind multiple receptors and less
favorable for the target to completely base pair with a single receptor, as the former
scenario would allow for channel pinching and the latter would not (Figure 4.2).

Figure 4.2 – Importance of nucleic acid oligomer design for flow valve diagnostics.
a) If the oligomer sequences are not carefully designed, it will be more favorable for target
strands to base pair with a single receptor strand and the channel will not constrict. b) Welldesigned oligomer sequences will allow the target to base-pair with multiple receptor strands,
leading to channel constriction and flow stoppage.

4.3 Conclusions
Future studies with flow valve devices should include improving the limits of
detection by modifying the device design, functionalization with two monoclonal
antibodies instead of a polyclonal antibody, and functionalization and testing with
DNA/RNA oligomers. All of these options should lead to improved biomarker
quantitation and broader applicability for flow valve devices. These prospects make
flow valve diagnostics an exciting new biomarker assay method with great potential to
enhance POC testing.
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